Is Mayne Pharma Group Limited a good investment? Mayne Pharma Group Limited (MYX.AX) is currently trading at 2.69 AUD. Market analysts have a consensus price target of 4.50 AUD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 8.87. This relatively low multiple may signal that Mayne Pharma Group Limited is undervalued compared to historical market norms.
Earnings Schedule: Mayne Pharma Group Limited is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is -0.34.
No, it does not currently pay a dividend.
Mayne Pharma Group Limited is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 0.31.
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
| Year | Total Dividends |
|---|---|
| ▸2023 |
0.03 AUD
|
| Jan. 27, 2023 | 0.0272 |
| ▸2011 |
0.00 AUD
|
| March 2, 2011 | 0.0005 |
| ▸2010 |
0.00 AUD
|
| Oct. 24, 2010 | 0.0010 |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 8, 2012 | 1.29 |
| Feb. 12, 2015 | 1.03 |
| June 30, 2016 | 1.05 |
| Jan. 18, 2023 | 1:20 |
Community Discussion